UVAX-1197

BIOLOGICAL2 trials

Sponsors

Uvax Bio LLC, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

AIDS/HIV - RelatedDisease Associated With AIDSHIV InfectionsHIV-1-infectionVaccine-Preventable Diseases

Early Phase 1

Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.

CompletedNCT06541093

Uvax Bio LLCAIDS/HIV - RelatedDisease Associated With AIDS, HIV Infections, Vaccine-Preventable Diseases

Start: 2024-01-30End: 2025-03-21Updated: 2025-05-23

Phase 1

A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV

SuspendedNCT06905275

National Institute of Allergy and Infectious Diseases (NIAID)HIV-1-infection

Start: 2025-07-07End: 2027-07-20Target: 25Updated: 2025-09-04

Related Papers

P-325. An Innovative Approach For An HIV-1 Prophylactic Vaccine – Results From A Phase I Clinical Trial

Open Forum Infectious Diseases2026-01-01